Few cancer treatments are as ferocious as CAR T cell therapy.
Often derived from a patient’s own immune cells, CAR T cells are genetically modified to seek out and destroy cancer cells. The FDA has approved treatments for deadly blood cancers, and coverings tackling autoimmune diseases and stopping tissue scarring in the guts and kidneys have shown promise.
Yet CAR T has struggled against solid tumors. Over 85 percent of cancers fall into this category. Solid tumors have an arsenal of sneaky tactics to evade or deactivate CAR T cells, eventually undermining the treatment.
This month, a Columbia University team broke through certainly one of the barriers with an upgraded design. They engineered a brand new, ultra-sensitive protein “hook” that seeks out CD70, a protein that dots the surfaces of multiple varieties of solid cancer cells—but at vastly different levels.
“Some molecules have been identified which are present in 25%, 50%, or 75% of tumor cells,” said study writer Michel Sadelain in a press release. “Though a therapy directed at those targets is perhaps successful…you possibly can’t cure any person for those who just eliminate a small fraction and even 90% of their tumor.”
In tests, the supercharged cancer-killers, dubbed HIT cells, detected and worn out cancer cells with extremely low levels of CD70—so low that the protein was undetectable using traditional methods. In kidney, ovarian, and pancreatic cancer grown from patients’ cells in petri dishes and in mouse models, HIT completely eliminated all signs of those tumors.
Like CAR T, the brand new approach is plug-and-play. The protein hook might be redesigned to focus on other faint cancer protein markers which have previously escaped detection.
“We hope our CD70-directed HIT cells help us discover a solution to eradicate all the tumor,”
said study writer Sophie Hanina.
A Mixed Bag
Our immune system naturally fights off cancer. T cells, for instance, roam the body on the lookout for threats. After they discover cancerous cells, they signal other immune cells to launch a coordinated effort to wipe out the cancer before it expands.
The identification process relies on antigens, proteins that dot the surfaces of cancer cells like beacons. But tumors are highly versatile and rapidly evolve their antigen signature, essentially cloaking themselves from immune attacks.
CAR T cells override the defense. Here, T cells are extracted from a patient’s body and genetically engineered with custom-designed protein hooks to grab onto cancer antigens.
Multiple blood cancers have a heavy coat of a single shared protein on their surfaces, making them an ideal goal for CAR T therapy. Solid tumors, nonetheless, are different. Tumors are dotted with a wide selection of antigens, a lot of that are present in normal tissues. This increases the probabilities CAR T might attack healthy cells and reduces its effectiveness.
Even for a similar antigen, some cells in solid tumors express high levels, others very low. The latter escape CAR T detection and linger as a reservoir that may regrow the tumor.
For a persistent solid cancer cure, “you may have to get all the way down to the very last cell,” said Sadelain.
In Plain Sight
A really perfect goal antigen needs to examine two boxes: It’s expressed across multiple tumor cell types, and at the identical time, it’s absent in normal cells.
The antigen in the brand new study, CD70, suits the bill. It occurs in a wide range of solid cancers, making it a precious goal beacon. But previous attempts targeting CD70 struggled to manage cancer in clinical trials. That is partly because cancer cells inside a single tumor have different levels of the antigen, and a few seemingly lack the marker altogether, allowing them to flee detection.
But are these cancer cells truly devoid of the antigen, or is it just that scientists, and the CAR T cells they’ve engineered, can’t find them using current methods?
Researchers can see most proteins under the microscope but only in the event that they’re at high enough levels. Reasonably than counting on conventional imaging, the team searched for CD70 gene expression in donated cancer patient samples. These lab models mimic the complexity of solid tumors.
CD70 antigens dotted each cell in multiple tumors, although at different levels of intensity. “We found that apparent CD70-negative tumor cells do in reality express low levels of CD70, though not at a level high enough to be eliminated by conventional CAR T cells,” wrote the team.
Taking aim at cancer cells with faint CD70 levels, the team tapped into their previous work genetically engineering cells to detect low-level antigens. The hooks on these HIT cells mimic those from a population of highly sensitive T cells naturally present in our bodies.
The team redesigned HIT cells to specifically goal CD70. Because normal cells don’t use this molecular pathway, HIT cells largely ignored them, lowering the chance of collateral damage.
“HIT cells are the subsequent generation of CAR T cells. They might be programmed like a CAR T cell, but they’ve the sensitivity of a natural T cell and may detect cancer cells which have only a vanishingly small variety of goal molecules,” said Hanina.
Sharp Shooter
Ovarian and pancreatic cancer cells have mixed levels of CD70. Several tests in highly aggressive models for these cancers found that HIT cells completely eradicated the tumors in petri dishes. The treatment also cleared cancer cells in several types of solid tumors in mice, even ones with low CD70 levels. Conventional CAR T only eliminated a fraction of the cancer.
A recent CAR T clinical trial targeting CD70 found CAR T cells could infiltrate and linger near kidney tumors, but their effectiveness was based on detection, which varied depending on the variety of CD70 beacons. Because HIT cells are more sensitive, they may seek out and kneecap more cancer cells.
But HIT cells can have uncomfortable side effects. Although CD70 isn’t expressed in most healthy tissues, its level skyrockets in immune cells during infections, which could trigger friendly fire. The team plans to analyze the treatment’s safety and efficacy in patients with ovarian cancer on the Columbia University Irving Medical Center.
If successful, the technology may benefit roughly 20 other varieties of solid cancer that express CD70, including deadly brain cancers comparable to glioblastoma.
“Curing solid tumors will not be easy, but this work solves one piece of the puzzle,” said Sadelain.